Living the Alzheimer’s Journey
Subscribe on your favorite platform
SUBSCRIBE
EXPERT ROUNDTABLE
Anti-Amyloid Therapies: Progress and Promise
February 7, 2024
4 pm Eastern time, 1 pm Pacific time
Steven E. Arnold, MD, Harvard Medical School
David A. Wolk, MD, Penn Memory Center
Moderator: Felicia Greenfield, MSW, LCSW, Penn Memory Center
Join us for this 75-minute roundtable as panelists share ideas and answer audience questions. The program will be streamed live. Pre-registered attendees will have access to Q&A and participate in polls.
Featured Episode
PLANNING
Progress on Anti-Amyloid Therapies: Roundtable Excerpt 1
Decades of research have helped elucidate the roles of amyloid plaques and tau tangles in Alzheimer’s disease, identify biomarkers of underlying pathology, and guide the development of new therapies. In this first of two excerpts from a recent roundtable, Dr. Steven E. Arnold, Massachusetts General Hospital, and Dr. David A. Wolk, Penn Memory Center, review our current understanding of amyloid and tau pathologies and the clinical trial data that led to the recent approval of Leqembi (lecanemab), the first fully FDA-approved drug for Alzheimer’s disease in over 20 years.